ATNF — 180 Life Sciences Share Price
Last Trade - 00:00- $214.15m
- $209.91m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | +433.08 | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
180 Life Sciences Corp., (180 Life Sciences) formerly KBL Merger Corp. IV., is a research and development company. The Company is focused on research into solving one of the diseases is inflammation. The Company consists of three programs developing drugs in separate areas of inflammation. The Company’s pipeline, including Fibrosis and Anti-TNF, SCAs and a7nAChR. The Fibrosis and Anti-TNF treats diseases like Dupuytren’s contracture, frozen shoulder, polycystic ovarian disease (POCD), nonalcoholic steatohepatitis (NASH). The SCAs includes chronic pain and early arthritis. The a7nAChR includes smoking cessation induced ulcerative colitis.
Directors
- Marc Feldmann
- Lawrence Steinman
- James Woody
- Ozan Pamir (29)
- Jonathan Rothbard
- Teresa DeLuca (55)
- Larry Gold (79)
- Frank Knuettel (55)
- Pamela Marrone (64)
- Donald McGovern
- Russell Ray (74)
- Last Annual
- December 31st, 2020
- Last Interim
- March 31st, 2021
- Incorporated
- September 7th, 2016
- Public Since
- June 27th, 2017
- No. of Shareholders
- 131
- No. of Employees
- 6
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 31,265,348
- Address
- 830 MENLO AVENUE, SUITE 100, MENLO PARK, 94025
- Web
- https://180lifesciences.com/
- Phone
- +1 6505070669
- Contact
- Jason Assad
- Auditors
- Marcum LLP
Latest News for ATNF
Upcoming events for ATNF
Similar to ATNF
9 METERS BIOPHARMA ORD
NASDAQ Capital Market
ABVC BIOPHARMA ORD
NASDAQ Capital Market
ACER THERAPEUTICS ORD
NASDAQ Capital Market
ADIAL PHARMACEUTICALS ORD
NASDAQ Capital Market
ADITXT ORD
NASDAQ Capital Market
FAQ
As of Today at 11:28 UTC, shares in 180 Life Sciences are trading at $6.96. This share price information is delayed by 15 minutes.
Shares in 180 Life Sciences last closed at $6.96 and the price had moved by -36.34% over the past 365 days. In terms of relative price strength the 180 Life Sciences share price has underperformed the S&P500 Index by -51.7% over the past year.
There is no consensus recommendation for this security.
180 Life Sciences does not currently pay a dividend.
180 Life Sciences does not currently pay a dividend.
180 Life Sciences does not currently pay a dividend.
To buy shares in 180 Life Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $6.96, shares in 180 Life Sciences had a market capitalisation of $214.15m.
Here are the trading details for 180 Life Sciences:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ATNF
Based on an overall assessment of its quality, value and momentum 180 Life Sciences is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like 180 Life Sciences. Over the past six months, its share price has outperformed the S&P500 Index by +17.03%.
As of the last closing price of $6.96, shares in 180 Life Sciences were trading +7.53% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for 180 Life Sciences.
180 Life Sciences' management team is headed by:
- Marc Feldmann -
- Lawrence Steinman -
- James Woody -
- Ozan Pamir -
- Jonathan Rothbard -
- Teresa DeLuca -
- Larry Gold -
- Frank Knuettel -
- Pamela Marrone -
- Donald McGovern -
- Russell Ray -
We do not have data on 180 Life Sciences' shareholders